SM
ADAP

Sabby Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Sabby Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-10,004
Closed -$120K – 315
2015
Q3 		$120K Buy
+10,004
New +$141K ﹤0.01% 363

Other funds holding ADAP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sabby Management's ADAP Position: Q4 2015 in Review

Sabby Management sold out of Adaptimmune Therapeutics (ADAP) in Q4 2015, closing a stake of 10,004 shares — an estimated $120K sold.

Sabby Management first reported a position in ADAP in Q3 2015 and held it in 1 quarter. The position peaked at $120K in Q3 2015. 49 funds tracked by Wall St. Rank hold ADAP as of Q4 2015.

  • Sabby Management reported no remaining Adaptimmune Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Sabby Management sold 10,004 Adaptimmune Therapeutics shares in Q4 2015, an estimated $120K.
  • Sabby Management first reported a position in Adaptimmune Therapeutics in Q3 2015 and held it in 1 quarter.
  • Sabby Management's Adaptimmune Therapeutics position peaked at $120K in Q3 2015.
  • 49 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2015.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.